[Clinical study of early interventions for ABO hemolytic disease of the newborn].
OBJECTIVE
To investigate therapeutic effect of high-dose intravenous immunoglobulin (IVIG) for early management of ABO hemolytic disease of the newborn (ABO-HDN).


METHODS
A total of 121 cases with ABO-HDN were randomly divided into treatment group (n=61) and control group (n=60). In addition to the routine treatment of the control group, IVIG were given at a daily dose of 400 mg/kg to the cases in the treatment group for 2-3 times, and therapeutic effects were evaluated and compared between the two groups.


RESULTS
The serum total billirubin concentration on the third day after treatment (153.42-/+45.21 micromol/L) and mean daily serum total billirubin concentration reduction (56.49-/+24.05 micromol/L) in treatment group were lower than those in the control group (P<0.01). The jaundice resolution time (23.51-/+11.19 h) and the phototherapy time (3.01-/+0.89 h) for billirubinemia treatment in treatment group were shorter than those in the control group (P<0.01). The patients in the the treatment group had higher hemoglobin level after treatment (15.59-/+2.01 g/L) than those of the control group (P<0.01).


CONCLUSIONS
High-dose IVIG can effectively arrest the progression of hemolytic disease, quickly reduce serum total billirubin concentration and shorten phototherapy time for early treatment of ABO-HDN.
Huang
Wei-min
WM
Department of Neonatology, Nangfang Hospital, Southern Medical University, Guangzhou 510515, China. hwmnet@21cn.com
Chen
Hong-wu
HW
Li
Ning
N
Yang
Ming
M
Jiao
Pei-yan
PY
D000017:ABO Blood-Group System; D001663:Bilirubin / Q000097:blood; D004899:Erythroblastosis, Fetal / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000188:drug therapy; D008297:Male; D013997:Time Factors; D016896:Treatment Outcome
D000017:ABO Blood-Group System; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D001663:Bilirubin